Advanced Filters
noise

Massillon, Ohio Clinical Trials

A listing of Massillon, Ohio clinical trials actively recruiting patient volunteers.

Found 148 clinical trials

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient adult participants aged 18 to 64 years with schizophrenia experiencing an acute exacerbation of psychosis. The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo …

18 - 64 years of age All Phase 2
D Doug Hart

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.

18 years of age All Phase 1

Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of every 7-week treatment cycle in …

18 years of age All Phase 1

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: Does ACP-211 work better than a …

18 - 65 years of age All Phase 2
J Jonathan Lockhart, MD

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

18 years of age All Phase 1
D Danielle Recasens

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.

18 - 85 years of age All Phase 3

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

18 - 75 years of age All Phase 2
A Ahmed A Hashem, PhD

Risk of Nerve Damage After Administration of Local Anesthesia

This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine …

18 - 55 years of age All Phase 1
R Richa Dawar, MD

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have …

18 years of age All Phase 2

A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ …

18 - 75 years of age All Phase 1

Simplify language using AI